Q-omics provides the consensus-scored FNTB profile across patient tissues and cancer cell-line models. FNTB expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, FNTB is differentially expressed in 13, with the highest sampling consensus in LIHC. Additionally, FNTB RNA expression shows 19,900 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight ACC, and LIHC as cancer lineages where FNTB shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FNTB — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FNTB survival associations across molecular data types. FNTB RNA expression shows survival associations in the most cancer types (24), followed by mutation status (3) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FNTB RNA expression–survival associations across cancer types. High FNTB expression shows unfavorable associations in ACC, STAD, BLCA and LIHC, but favorable associations in BRCA and MESO. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for FNTB RNA expression.
This table summarizes FNTB tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 5. The strongest signals are observed in LIHC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for FNTB. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FNTB shows higher tumor expression in LIHC, KIRP, COAD, LUAD, KIRC and BRCA. The LIHC box plot shows higher FNTB RNA expression in tumor versus normal tissue (log2 FC = +0.872, t-test p < 0.001).
This table shows molecular features associated with FNTB in patient tissues and cancer cell lines. In patient samples, FNTB shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, FNTB RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in OVARY and LARGE_INTESTINE.
